Building a CAR garage: Preparing for the delivery of commercial CAR T cell products at Memorial Sloan Kettering Cancer Center Journal Article


Authors: Perica, K.; Curran, K. J.; Brentjens, R. J.; Giralt, S. A.
Article Title: Building a CAR garage: Preparing for the delivery of commercial CAR T cell products at Memorial Sloan Kettering Cancer Center
Abstract: Two commercial chimeric antigen receptor (CAR) T cell therapies for CD19-expressing B cell malignancies, Kymriah and Yescarta, have recently been approved by the Food and Drug Administration. The administration of CAR T cells is a complex endeavor involving cell manufacture, tracking and shipping of apheresis products, and management of novel and severe toxicities. At Memorial Sloan Kettering Cancer Center, we have identified 8 essential tasks that define the CAR T cell workflow. In this review, we discuss practical aspects of CAR T cell program development, including clinical, administrative, and regulatory challenges for successful implementation. © 2018 The American Society for Blood and Marrow Transplantation
Keywords: acute lymphoblastic leukemia; chimeric antigen receptor; cytokine release syndrome; diffuse large b cell lymphoma; cellular therapy; car t cells
Journal Title: Biology of Blood and Marrow Transplantation
Volume: 24
Issue: 6
ISSN: 1083-8791
Publisher: Elsevier Inc.  
Date Published: 2018-06-01
Start Page: 1135
End Page: 1141
Language: English
DOI: 10.1016/j.bbmt.2018.02.018
PROVIDER: scopus
PUBMED: 29499327
PMCID: PMC6625528
DOI/URL:
Notes: Review -- Export Date: 2 July 2018 -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Renier J Brentjens
    265 Brentjens
  2. Sergio Andres Giralt
    754 Giralt
  3. Kevin Joseph Curran
    87 Curran
  4. Karlo Perica
    2 Perica